



First Quarter 2015 Financial Results

29th April 2015



Laboratorios Farmacéuticos Rovi, S.A. and Subsidiaries
Investor Relations



ROVI – First Quarter 2015 Financial Results

ROVI reports EBITDA growth of 7% and net profit growth of 9%

- **Operating revenue increased by 5% to 60.8 million euros in the three-month period ended 31 March 2015, mainly driven by the strength of the toll manufacturing business which grew by 11%, and by the prescription-based pharmaceutical business, where sales rose 3%, outperforming the prescription market¹ by 2.5 percentage points. Total revenue increased by 4% to 61.1 million euros in the first quarter of 2015.**
- **ROVI expects operating revenue to grow from mid to high single digit for the full year 2015, despite (i) a 0.8% slight rise in Spanish pharmaceutical market according to Farmaindustria², and (ii) zero to negative spending growth on medicine in Spain for the period 2014-2018 forecast by IMS Health³.**
- **Sales of Bemiparin in Spain performed well in the three-month period ended 31 March 2015, with a 10% increase to 12.5 million euros. Bemiparin total sales increased by 1% to 18.9 million euros in the first quarter of 2015.**
- **Sales of Absorcol[®] and Vytorin[®], the first of the five licenses of Merck Sharp & Dohme (MSD), increased by 11% to 5.4 million euros in the first quarter of 2015. Sales of Medicebran[®] and Medikinet[®], specialty products from Medice indicated for the treatment of ADHD (Attention Deficit and Hyperactivity Disorder) in children and teenagers, launched in December 2013 and marketed on exclusivity basis by ROVI in Spain, increase by 12% to 2.0 million euros in the first quarter of 2015. Sales of Corlantor[®], from Servier, increased by 4% to 3.4 million euros in the three-month period ended 31 March 2015.**
- **Sales of Hirobriz[®] Breezhaler[®] and Ulunar[®] Breezhaler[®], both inhaled bronchodilators from Novartis for patients with respiratory difficulties due to a pulmonary disease known as Chronic Obstructive Pulmonary Disease (COPD),**

¹IMS data

²<http://www.farmaindustria.es/web/indicador/analisis-de-la-evolucion-del-gasto-farmaceutico-publico-en-espana-mes-mes-2/>

³<http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=266e05267ae9410VgnVCM10000076192ca2RCRD&vgnnextchannel=736de5fda6370410VgnVCM10000076192ca2RCRD&vgnnextfmt=default>



launched in Spain in the fourth quarter of 2014, reached 1.0 million euros in the first quarter of 2015.

- **EBITDA increased by 7% to 9.6 million euros in the three-month period ended 31 March 2015, compared to the same period of the previous year, reflecting a 0.2 percentage points rise in the EBITDA margin to 15.8% in the first quarter of 2015 up from 15.6% in the first quarter of 2014.**
- **Net profit increased by 9% to 6.5 million euros in the first quarter of 2015, compared to the same period of the previous year.**
- **ROVI will propose to the Shareholders General Meeting a dividend of 0.1690 euros per share on 2014 earnings. This dividend would mean an increase of 5% compared to the dividend on 2013 earnings (€0.1612).**

Madrid (Spain), 29th April 2015, 8:00 AM CET - ROVI released today its financial results for the first quarter of 2015.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said that *"in the first quarter of 2015, we reached a 5% operating revenue growth mainly driven by the strength of our specialty pharmaceutical area and our toll manufacturing area, especially of the injectables plant. Sales of prescription-based pharmaceutical products rose 3% in the first quarter of 2015 despite the difficulties that the Spanish pharmaceutical market is going through. Prescription-based pharmaceutical market covering the 12-month period ending March 2015 decreased by -0.1%, according to IMS. Nevertheless, we forecast continue to grow thanks to, among others, our flagship product, Bemiparin, which is contributing significantly to this growth. In particular, in the first quarter of 2015, Bemiparin sales increased by 10% in the domestic market.*

Furthermore, we expect our entrance in the respiratory market through the launch of Hirobriz® Breezhaler® and Ulunar® Breezhaler®, from Novartis, in Spain in the fourth quarter of 2014, as well as our entrance in the urology field through the launch of Volutsa®, from Astellas Pharma, in Spain in the first quarter of 2015, to contribute to growth in the coming years. In addition, the MSD agreement will allow us to launch four additional new products in the next 4 years, underpinning our belief in the sustainability of the long term outlook for the company.

ROVI's R&D pipeline continues to hold strong potential to drive the company's growth in future years. We are very excited with the potential of our long acting injectable technology (ISM®); we expect to start a phase III trial with our ISM® technology in 2015 as well as to develop a new phase I study for another candidate next year. Likewise, on the 9th of February, the assessment process started in order for ROVI to be granted the Marketing Authorisation in



Europe of a low-molecular-weight heparin, a biosimilar of enoxaparin. We are hopeful of obtaining authorisation to market this drug and expect to have news from the European assessment process in the coming months."

1. Financial highlights

€ million	Q1 2015	Q1 2014	Growth	% Growth
Operating revenue	60.8	57.6	3.1	5%
Other income	0.3	0.9	-0.6	-67%
Total revenue	61.1	58.6	2.5	4%
Cost of sales	-25.4	-23.5	-1.9	8%
Gross profit	35.7	35.1	0.6	2%
<i>% margin</i>	<i>58.8%</i>	<i>60.9%</i>		-2.1pp
R&D expenses	-3.2	-3.0	-0.2	8%
Other SG&A	-22.9	-23.2	0.2	-1%
EBITDA	9.6	9.0	0.6	7%
<i>% margin</i>	<i>15.8%</i>	<i>15.6%</i>		0.2pp
EBIT	7.1	6.9	0.3	4%
<i>% margin</i>	<i>11.8%</i>	<i>12.0%</i>		-0.2pp
Net profit	6.5	5.9	0.5	9%

Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding.

The consolidated financial statements of Grupo ROVI for the first quarter of 2015 and the comparative information for 2014 (balance sheet) and for the first quarter of 2014 (consolidated income statement and cash flow statement) are attached to this report (see Appendix 1).

2. Performance of the Group

Operating revenue increased by 5% to 60.8 million euros in the three-month period ended 31 March 2015, mainly driven by the strength of the toll manufacturing business which grew by 11%, and by the specialty pharmaceutical business, where sales rose 3%, outperforming the prescription market¹ by 2.5 percentage points. Total revenue increased by 4% to 61.1 million euros in the first quarter of 2015.

¹ IMS data



Sales of **prescription-based pharmaceutical** products rose 3% to 35.6 million euros in the three-month period ended 31 March 2015.

ROVI's low molecular weight heparin (LMWH), **Bemiparin**, performed well in Spain in the first quarter of 2015, with sales up 10% to 12.5 million euros. International sales decreased by 12% to 6.3 million euros. This decrease was specifically linked to the first quarter of 2015 and ROVI expects Bemiparin marketing in China and Brasil, forecast for the second half of 2015, as well as the launch of the product in new countries, such as Qatar in the first quarter of 2015, to contribute to stable sales in 2015. Bemiparin total sales increased by 1% to 18.9 million euros in the first quarter of 2015.

Sales of **Vytorin**[®] and **Absorcol**[®], the first of the five licenses of MSD, launched in January 2011, increased by 11% to 5.4 million euros in the first quarter of 2015.

Sales of **Hirobriz**[®] **Breezhaler**[®] and **Ulunar**[®] **Breezhaler**[®], both inhaled bronchodilators from Novartis for patients with respiratory difficulties due to a pulmonary disease known as Chronic Obstructive Pulmonary Disease (COPD), launched in Spain in the fourth quarter of 2014, reached 1.0 million euros in the first quarter of 2015.

Sales of **Medicebran**[®] and **Medikinet**[®], specialty products from Medice indicated for the treatment of ADHD (Attention Deficit and Hyperactivity Disorder) in children and teenagers, launched in December 2013 and marketed on exclusivity basis by ROVI in Spain, increased by 12% to 2.0 million euros in the first quarter of 2015.

Sales of **Corlentor**[®], a specialty product for stable angina and chronic heart failure from Laboratoires Servier, increased by 4% to 3.4 million euros in the three-month period ended 31 March 2015.

Sales of **Volutsa**[®], a specialty product from Astellas indicated for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia, launched in Spain in February 2015, reached 0.4 million euros in the first quarter of 2015 (see section 6.1).

Sales of **Exxiv**[®], a selective COX-2 inhibitor from Merck Sharp & Dohme (MSD), decreased by 10% to 1.5 million euros in the three-month period ended 31 March 2015, mainly due to a continued deceleration of the COX-2 market.

Sales of **Thymanax**[®], an innovative antidepressant from Laboratoires Servier and for which ROVI has a co-marketing agreement covering Spain, decreased by 24% to 2.0 million euros in the three-month period ended 31 March 2015.



According to IMS, Spanish prescription-based pharmaceutical market slightly increased by 0.5% in the first quarter of 2015 compared to the same period of the previous year. Nevertheless, ROVI prescription-based pharmaceutical product sales rose 3% in the first quarter of 2015, beating the market by 2.5 percentage points.

Also, prescription-based pharmaceutical market covering the 12-month period ending March 2015 decreased by -0.1%. However, ROVI prescription-based pharmaceutical product sales rose 8% in the last year.

In addition, a slight 0.8% increase and a 0.2% fall of Spanish pharmaceutical expenditure is expected for 2015 and 2016 respectively, according to Farmaindustria¹, and zero to negative spending growth on medicine in Spain for the period 2014-2018 is forecast by IMS Health². Despite the difficult situation that the pharmaceutical industry is still going through, ROVI forecasts continue to grow.

Sales of **contrast imaging agents** and other hospital products increased by 7% to 6.4 million euros in the three-month period ended 31 March 2015.

Sales of **over-the-counter pharmaceutical products** ("OTC") **and other** remained stable at 1.6 million euros in the three-month period ended 31 March 2015 compared to the same period of the previous year. EnerZona[®], a range of products based on the principles of the Zone Diet, performed well with sales up 6% to 1.0 million euros.

Toll manufacturing sales increased by 11% to 17.1 million euros in the three-month period ended 31 March 2015 compared to the same period of the previous year. The positive evolution of the injectables plant, whose revenue increased by 66% to 7.3 million euros in the first quarter of 2015 largely offset the 1.2 million euros revenue decline in the Frosst Ibérica plant to 9.8 million euros in the first quarter of 2015, as a consequence of a lower production for Merck Sharp and Dohme (MSD).

Sales outside Spain increased by 9% to 22.3 million euros in the first quarter of 2015 compared with the same period of previous year. Sales outside Spain represented 37% of operating revenue in the first quarter of 2015 compared to 36% in the first quarter of 2014.

Gross profit increased by 2% to 35.7 million euros in the three-month period ended 31 March 2015, reflecting a decrease of 2.1 percentage points in the gross margin to 58.8% in the first quarter of 2015 from 60.9% in the first quarter of 2014. Excluding the impact of other income (subsidies), which decreased by 67% in the first quarter of 2015, gross margin

¹ <http://www.farmaindustria.es/web/indicador/analisis-de-la-evolucion-del-gasto-farmaceutico-publico-en-espana-mes-mes-2/>

² <http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=266e05267ae a9410VgnVCM10000076192ca2RCRD&vgnnextchannel=736de5fda6370410VgnVCM10000076192ca2RCRD&vgnnextfmt=default>

decreased to 58.3% in the first quarter of 2015 from 59.3% in the first quarter of 2014 mainly due to a reduction of the amount invoiced to MSD, who contribute high margins. The decrease of the Bemiparin raw material cost impacted positively in the first quarter of 2015 gross margin.

Research and development expenses increased by 8% to 3.2 million euros in the three-month period ended 31 March 2015, reflecting ROVI investments in products that are under development, mainly related to the Risperidone-ISM[®] project.

Selling, general and administrative expenses decreased by 1% to 22.9 million euros in the three-month period ended 31 March 2015, compared to the same period of the previous year, mainly due to a strict cost control.

EBITDA increased by 7% to 9.6 million euros in the three-month period ended 31 March 2015, compared to the same period of the previous year, reflecting a 0.2 percentage points rise in the EBITDA margin to 15.8% in the first quarter of 2015 up from 15.6% in the first quarter of 2014.

Depreciation and amortisation expenses increased by 16% to 2.4 million euros in the first quarter of 2015, mainly as a result of the new property plant and equipment and intangible assets purchases made during the last twelve months.

EBIT increased by 4% to 7.1 million euros in the first quarter of 2015, compared to the first quarter of 2014, reflecting a 0.2 percentage points decline in the EBIT margin to 11.8% down from 12.0% in the first quarter of 2014.

Financial expense decreased by 59% in the first quarter of 2015, compared to the same period of the previous year, mainly due to the registration, in the first quarter of 2014, of the interests related to the return of the loan granted by the Ministry of Health, Social Services and Equality for the development of the vaccine project in 2009. The financial expense line also includes the implicit interests registered as a result of the recognition at fair value of reimbursable loans, at zero interest rate, granted by Public Administrations.

Financial income decreased by 46% in the first quarter of 2015, compared to the first quarter of 2014, mainly as a result of the reduction of interest on late payments from certain hospitals registered in the first quarter of 2015.

The **effective tax rate** was 6.5% in the first quarter of 2015 compared to 4.8% in the first quarter of 2014. This favourable effective tax rate is due to the deduction of existing research and development expenses and the capitalisation of negative tax bases from Frosst Ibérica, S.A. As of 31 December 2014, Frosst Ibérica negative tax bases amounted to 50.1 million

euros, of which 7.7 million euros will be used in the 2014 income tax and 1.8 million euros in the first quarter of 2015.

On 27 November 2014, a deep tax reform was approved by law (see <http://www.boe.es/boe/dias/2014/11/28/pdfs/BOE-A-2014-12328.pdf>) in order to simplify taxes, reduce withholding taxes and improve Spanish companies' competitiveness. These tax measures, that have been in force since January 2015, will positively affect ROVI income statement and income tax payable rate. ROVI expects to maintain an effective tax rate from mid to high single digit for the following years.

Among the tax measures that will affect corporate income tax, it should be noted that:

- ✓ the tax rate is reduced from 30% to 28% in 2015 and to 25% from 2016;
- ✓ tax losses may offset positive taxable income faster and without time limit; and
- ✓ R&D tax credit schedule is maintained.

Net profit amounted to 6.5 million euros, a 9% increase compared to the same period of the previous year.

ROVI will pay a **dividend** of 0.1690 euros per share on 2014 earnings if the Shareholders General Meeting approves the application of the 2014 profit, under proposal of ROVI's Board of Directors. This proposed dividend would mean an increase of 5% compared to the dividend on 2013 earnings (0.1612 euros per share) and implies a 35% pay-out.

Javier López-Belmonte Encina, Chief Financial Officer of ROVI, said that, "*we are satisfied with the results for the first quarter of 2015. Operating revenue increased by 5% compared to the first quarter of 2014, fulfilling our expectations despite the difficulties in the economic and regulatory environments. We attribute this out-performance to the strength of our injectables toll manufacturing business as well as of our leading products, which continue to gain share in their various market segments. EBITDA margin increased in the first quarter of 2015, mainly as a result of the operating leverage contributed by our last product launches. It is very gratifying to witness the strength of our balance sheet and our excellent capacity to generate cash, which allow us to finance organic growth through the launch of new products, such as Volutsa[®], Ulunar[®], Hirobriz[®], Vytarin[®] or Medikinet[®], and to be in a strong position to benefit in the current operating environment as we will pay attention to potential opportunities to expand our sales base and improve the utilisation of our asset base*".

3. Balance Sheet items

3.1 Capital expenditure

ROVI invested 1.4 million euros in the first quarter of 2015, compared to 1.7 million euros in the first quarter of 2014. Of this amount:

- 0.6 million euros corresponds to investment capex related to the injectables facility mainly due to the preparation of the plant for the development of the ISM[®] project, versus 0.8 million euros in the first quarter of 2014;
- 0.4 million euros corresponds to investment capex related to the Granada facility mainly for the future implementation of a third production line, versus 0.3 million euros in the first quarter of 2014;
- 0.1 million euros corresponds to investment capex related to the Alcalá (Frosst Ibérica) facility, the same amount invested in the first quarter of 2014; and
- 0.3 million euros corresponds to expenditure on maintenance and other, vs. 0.5 million euros in the first quarter of 2014.

3.2 Debt

As of 31 March 2015, ROVI had total debt of 35.9 million euros. Debt with public administration, which is 0% interest rate debt, represented 43% of total debt as of 31 March 2015.

<i>In thousand euros</i>	31 March 15	31 December 14
Bank borrowings	20,425	20,560
Debt with public administration	15,514	15,746
Total	35,939	36,306

3.3 Free cash flow

Free cash flow (net cash generated (used) from operating activities minus (plus) property, plant and equipment and intangible assets purchases (sales) plus interest received) increased to 1.0 million euros in the first quarter of 2015 from -5.0 million euros in the first quarter of 2014 mainly due to (i) the increase of 1.2 million euros in the "trade and other receivables" item in the first quarter of 2015, compared to an increase of 7.0 million euros in the first quarter of 2014 and (ii) the increase of 1.7 million euros in the "inventories" item, compared to an increase of 2.7 million euros in the first quarter of 2014 as a result of a larger Bemiparin production in the first quarter of last year.

3.4 Net and gross cash position

As of 31 March 2015, ROVI had a gross cash position of 29.1 million euros, compared to 28.0 million euros as of 31 December 2014, and net cash position (available-for-sale financial assets plus deposits plus cash and cash equivalents minus short term and long term financial debt) of -6.8 million euros, compared to -8.3 million euros as of 31 December 2014.

3.5 Working capital

The increase in working capital in the first quarter of 2015 was mainly due to (i) a 1.7 million euros increase in inventories as a result of the stock of the products recently launched, Ulunar and Volutsa; (ii) an increase in the "trade and other receivables" item of 1.2 million euros and (iii) a decrease in the "trade and other payables" line of 5.7 million euros. Cash and cash equivalents increased by 1.2 million euros in the first quarter of 2015.

As of 31 March 2015, Social Security and Public Administrations total debt with ROVI amounted to 13.8 million euros, of which 12.2 million euros in Spain and the other 1.6 million euros in Portugal. Almost all this debt is expected to be collected through the usual channels.

4. Guidance for 2015

ROVI expects **operating revenue to grow from mid to high single digit for the full year 2015**, despite (i) a 0.8% slight rise in Spanish pharmaceutical market according to Farmaindustria¹, and (ii) zero to negative spending growth on medicine in Spain for the period 2014-2018 forecast by IMS Health².

ROVI expects its growth drivers to be Bemiparin, the new license agreements (Volutsa[®], Ulunar[®], Hirobriz[®] and Medikinet[®]), contribution from Vytorin[®] and Absorcol[®], its existing portfolio of specialty pharmaceuticals, new product distribution licenses and new contracts in the toll manufacturing area.

5. Research and Development update

As it has been previously commented, the R&D programs of ROVI are mainly focused on the Glycomics and the ISM[®] platforms, the latest an own proprietary drug delivery system aimed to improve patients' therapeutic compliance.

¹ <http://www.farmaindustria.es/web/indicador/analisis-de-la-evolucion-del-gasto-farmaceutico-publico-en-espana-mes-mes-2/>

² <http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vqnextoid=266e05267aea9410VqnVCM10000076192ca2RCRD&vqnextchannel=736de5fda6370410VqnVCM10000076192ca2RCRD&vqnextfmt=default>

After being built in Madrid a manufacturing plant for new medicines using the ISM® technology (equipped with very innovative machinery for filling solid compounds in syringes), ROVI is now expanding its facilities. The company is constructing a second plant that will allow manufacturing new ISM products for high potency active principles, such as letrozole.

In the first quarter of 2015 patients' follow up of the PRISMA-2 study³ was complete; this is a phase II trial carried out in several USA centres for evaluating the safety and pharmacokinetics of Risperidone ISM® after four monthly intramuscular doses (gluteus or deltoids) in schizophrenic subjects. The results from this study are expected by the third quarter of 2015.

With regards to Glycomics, on last February 9th, after the end of the validation phase, the assessment process started in order for ROVI to be granted the Marketing Authorisation in Europe of a low-molecular-weight heparin, a biosimilar of enoxaparin. The European registration process for this drug is expected to take between five and twelve months from that date.

6. Key operating and financial events

6.1 ROVI announces the agreement to market Volutsa® in Spain

ROVI announces it has signed an agreement with Astellas Pharma, S.A. (Astellas) to market Volutsa® (solifenacin succinate and tamsulosin hydrochloride) in Spain, which corresponds to Astellas' Vesomni® product.

Under the terms of this marketing agreement, ROVI will undertake the promotion and distribution in Spain of Volutsa®, a modified release tablet containing two active substances, solifenacin and tamsulosin. Solifenacin is an anticholinergic drug and tamsulosin belongs to a drugs group called alpha-antagonists. Volutsa® is indicated for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.

When the prostate becomes enlarged, urinary problems (voiding symptoms) such as urinary hesitancy (difficulty to initiate urination), reduction of the flow of urine (weak stream), urine leakage and sensation of incomplete emptying of the bladder, may occur. At the same time, the bladder may also be affected and it contracts spontaneously at times when urination is delayed. This causes bladder (storage) symptoms such as changes in the sensation of the

³ *Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia (PRISMA-2).*
[<http://clinicaltrials.gov/show/NCT02086786>].



bladder, urgency (having an uncontrollable urge to urinate) and a high urinary frequency to occur. Solifenacin reduces involuntary contractions of the bladder and increases the amount of urine that the bladder can hold. Tamsulosin allows the urine to pass more easily through the urethra, thereby facilitating urination.

ROVI started to market Volutsa® in the first quarter of 2015, at the same time Astellas started commercialising Vesomni®.

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es

For further enquiries, please contact:

Juan López-Belmonte Encina
Chief Executive Officer
+34 913756235
jlopez-belmonte@rovi.es
www.rovi.es



Javier López-Belmonte Encina
Chief Financial Officer
+34 913756266
javierlbelmonte@rovi.es
www.rovi.es

Marta Campos Martínez
Investor Relations
+34 912444422
mcampos@rovi.es
www.rovi.es

Forward-looking statements

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except in case of substantive changes. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date subsequent to the date of this press release.



APPENDIX 1

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF 31 MARCH 2015 AND 31 DECEMBER 2014

(Thousands of euros)

	31 March 2015	31 December 2014
ASSETS		
Non-current assets		
Property, Plant and Equipment	72,496	73,593
Intangible assets	17,287	17,206
Deferred tax assets	8,445	8,280
Available-for-sale financial assets	71	71
Financial receivables	137	137
	98,436	99,287
Current assets		
Inventories	69,228	67,567
Trade and other receivables	64,888	63,678
Current income tax assets	1,473	4,117
Cash and cash equivalents	27,855	26,671
	163,444	162,033
Total assets	261,880	261,320



LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF 31 MARCH 2015 AND 31 DECEMBER 2014

(Thousands of euros)

	31 March 2015	31 December 2014
EQUITY		
Capital and reserves attributable to shareholders of the company		
Share capital	3,000	3,000
Legal reserve	600	600
Treasury shares	(2,672)	(2,813)
Retained earnings and voluntary reserves	157,760	133,569
Profit for the period	6,451	24,116
Reserve for available-for-sale assets	(1)	(2)
Total equity	165,138	158,470
LIABILITIES		
Non-current liabilities		
Financial debt	30,990	32,032
Deferred income tax liabilities	1,684	1,818
Non-current deferred revenue	6,904	6,883
	39,578	40,733
Current liabilities		
Trade and other payables	49,275	55,018
Financial debt	4,949	4,274
Current deferred revenue	640	798
Provisions for other liabilities and charges	2,300	2,027
	57,164	62,117
Total liabilities	96,742	102,850
Total equity and liabilities	261,880	261,320



LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS FOR THE THREE-MONTH PERIODS ENDED 31
MARCH 2015 AND 31 MARCH 2014

(Thousands of euros)

	Three-month periods ended 31 March	
	2015	2014
Revenue	60,766	57,624
Cost of sales	(25,369)	(23,481)
Employee benefit expenses	(15,602)	(14,589)
Other operating expenses	(10,533)	(11,524)
Depreciation, amortisation and impairment charges	(2,432)	(2,090)
Recognition of government grants on non financial non-current assets and other	312	947
OPERATING PROFIT	7,142	6,887
Finance income	99	185
Finance costs	(344)	(841)
FINANCE COSTS - NET	(245)	(656)
PROFIT BEFORE INCOME TAX	6,897	6,231
Income tax	(446)	(301)
PROFIT FOR THE PERIOD	6,451	5,930



LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR THE THREE-MONTH PERIODS ENDED 31
MARCH 2015 AND 31 MARCH 2014

(Thousands of euros)

	Three-month periods ended 31 March	
	2015	2014
Cash flows from operating activities		
Profit before income tax	6,897	6,231
Adjustments for non-monetary transactions:		
Amortisation	2,432	2,090
Interest income	(99)	(185)
Impairment losses	91	2,012
Interest expense	344	841
Net changes in provisions	273	(247)
Grant for non-financial fixed assets and distribution licence income	106	(1,018)
Changes in working capital		
Trade and other receivables	(1,404)	(6,070)
Inventories	(1,809)	(4,070)
Trade and other payables	(6,293)	(4,735)
Other collections and payments		
Collection for distribution licenses	-	100
Interest paid	(85)	(6)
Income tax cash flow	1,900	1,500
Net cash generated (used) from operating activities	2,353	(3,557)
Cash flows from investing activities		
Purchases of intangible assets	(567)	(268)
Purchases of property, plant and equipment	(855)	(1,388)
Proceeds of property, plant and equipment	6	-
Interest received	48	185
Net cash generated (used) in investing activities	(1,368)	(1,471)
Cash flows from financing activities		
Repayments of financial debt	(322)	(1,091)
Proceeds from financial debt	305	10
Purchase of treasury shares	(330)	(426)
Reissue of treasury shares	546	-
Net cash generated in financing activities	199	(1,507)
Net (decrease)/increase in cash and cash equivalents	1,184	(6,535)
Cash and cash equivalents at beginning of the period	26,671	19,401
Cash and cash equivalents at end of the period	27,855	12,866